Liminatus Pharma, Inc. (LIMN) Stock

NASDAQ: LIMNHealthcare company in the biotechnology industry, based in Cerritos, CA.

Liminatus Pharma stock price chart

LIMN interactive chart →

LIMN stock quote & key statistics

Liminatus Pharma earnings per share

Income →
Earnings per share

Liminatus Pharma revenue & net income

Income →
RevenueNet income

Liminatus Pharma annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$0-$10.2M-$15.04
FY2024$0-$2.9M-$20.24
FY2023$0-$1.2M-$4.00
FY2022$0-$2.9M$0.12

Fiscal year ending December 31. Source: company filings via EODHD.

About Liminatus Pharma, Inc.

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.

Liminatus Pharma stock FAQ

What is the Liminatus Pharma stock ticker symbol?

Liminatus Pharma, Inc. trades on the NASDAQ under the ticker symbol LIMN.

What sector and industry is Liminatus Pharma in?

Liminatus Pharma, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Liminatus Pharma have?

Liminatus Pharma, Inc. has about 1 full-time employees.

What were Liminatus Pharma's revenue and earnings last fiscal year?

Liminatus Pharma reported revenue of $0 and net income of -$10.2M in fiscal 2025, with earnings per share of -$15.04.

When did Liminatus Pharma go public?

Liminatus Pharma stock began trading on May 1, 2025.

Biotechnology stocks

All Healthcare stocks →